Date: September 25, 2026

To	**To**
Listing Compliance Department	BSE Limited
National Stock Exchange of India Limited,	1st Floor, New Trading Ring,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,	Rotunda Building, P.J. Towers,
Bandra Kurla Complex, Bandra (E),	Dalal Street,
Mumbai-400051	Mumbai – 400001
Symbol: BALPHARMA	Scrip Code: 524824

Sub: Change in Designation of Directors and Reconstitution of Statutory Committees

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Members of the Company, at the 39th Annual General Meeting of the Company held on Thursday, September 24, 2026, have approved the following:

a. Re-appointment of Mr. Ravindra Kumar Kothari (DIN: 03418320) as a Director liable to retire by rotation pursuant to Section 152 of the Companies Act, 2013.

b. Change in designation of Mr. Ravindra Kumar Kothari (DIN: 03418320) from Non-Executive Director to Whole-Time Director, designated as Executive Director, with effect from October 1, 2026

c. Change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole-Time Director to Non-Executive Director, with effect from October 1, 2026.

The above changes in designation were earlier recommended by the Nomination and Remuneration Committee at its meeting held on August 12, 2026 and subsequently approved by the Board of Directors at its meeting held on same day subject to the approval of the Members of the Company at the 39th Annual General Meeting. The requisite approval of the Members has now been obtained.

The disclosures required under Regulation 30 of the SEBI LODR Regulations read with the applicable SEBI Circular are enclosed herewith as Annexure A.

BAL PHARMA LIMITED

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Reconstitution of Statutory Committees

Consequent upon the approval of the Members for the change in designation of Mr. Ravindra Kumar Kothari from Non-Executive Director to Whole-Time Director (Executive Director) and Mr. Virupakshaya Himesh from Whole-Time Director to Non-Executive Director, the Nomination and Remuneration Committee ("NRC") and the Stakeholders' Relationship Committee ("SRC") of the Company have been reconstituted with effect from October 1, 2026, in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The proposed reconstitution of the NRC and SRC was recommended by the NRC at its meeting held on August 12, 2026 and approved by the Board of Directors at its meeting held on the same day, subject to the approval of the Members for the aforesaid change in designation of the Directors.

Pursuant to the approval accorded by the Members at the 39th Annual General Meeting held on September 24, 2026, the NRC and SRC have been reconstituted with effect from October 1, 2026, as follows:

1. Mr. Virupakshaya Himesh has been inducted as a Member of the NRC and SRC.
2. Mr. Ravindra Kumar Kothari has ceased to be a Member of the NRC and SRC.

Accordingly, the revised composition of the NRC and SRC shall be effective from October 1, 2026.

Please takes this intimation on your records

Thanking You.

For Bal Pharma Limited

Shreepad a ML

Digitally signed by Shreepada ML
DN: cn=Shreepada ML, o, ou, email=sribhat111@gmail.com, c=US
Date: 2026.09.25 16:48:18 +05'30'

BAL PHARMA LTD CIN L85110KA1987PLC008368 BENGALURU

Shreepada ML
Company Secretary and Compliance officer
ICSI M No : A66681

BAL PHARMA LIMITED

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Annexure: A

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are given as under.

Change of Designations of Directors: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	**Mr. Ravindra Kumar Kothari**	**Mr. Virupakshaya Himesh**
Reason for change	Change in designation from Non-Executive Director to Executive Director	Change in designation from Executive Director to Non-Executive Director
Date of appointment/re-designation	Change of Designation will effective from 01st October 2026	Change of Designation will effective from 01st October 2026
Term of appointment	Not applicable (Director already on the Board)	Not applicable (Director already on the Board)
Brief profile	Not applicable (Director already on the Board)	Not applicable (Director already on the Board)
disclosure of relationships between directors (in case of appointment of a director).	Not applicable	Not applicable
Information as required under Circular No. LIST/COMP/14/2018- 19 and NSE/CML/ 2018/02 dated June 20, 2018, issued by the BSE and NSE, respectively	The Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	The Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
Shareholdings	500	28,420

Shreepada ML
Digitally signed by Shreepada ML
DN: cn=Shreepada ML, o, ou, email=sribhat111@gmail.com, c=US
Date: 2026.09.25 16:48:44 +05'30'